At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
In Brief
A Phase 2 clinical trial evaluating bortezomib and rituximab for Post-transplant Lymphoproliferative Disease and 3 related conditions. Completed, enrolled 7 participants across 3 sites.
Detailed Summary
Post transplant lymphoproliferative disease (PTLD) is a type of B-cell non-Hodgkin lymphoma that occurs in patients with weakened immune systems due to immunosuppressive medications taken after organ or stem cell transplantation. This is usually related to a virus called Epstein-Barr (EPV). Rituximab is a type of drug called an "antibody" that specifically destroys both normal and cancerous B-cells, and is commonly used for PTLD. Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) to treat multiple myeloma and a B-cell non-Hodgkin lymphoma called Mantle Cell Lymphoma, and shows significant activity in lymphoma cells caused by EBV. In this research study, we hope to learn if the addition of bortezomib to rituximab treatment can increase the rate of complete remissions and cures of PTLD after organ or stem cell transplant.
Study Details
Timeline
Interventions
Given intravenously on days 1, 4, 8 and 11 of every cycle
given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles